During the 10 years since the last edition of this volume our knowledge on malignant lymphomas, especially on extranodal lymphomas, has increased. This volume is an expanded and completely revised edition, now based on the WHO classification. The parallels to the updated Kiel classification and the REAL classification are indicated. The information is organized in organ-specific chapters, comprising the well-known nodal lymphoma entities as well as all known extranodal lymphomas and the different organ-specific clinico-pathological entities: lymphomas of the spleen, the gastrointestinal tract, the skin, etc. In addition to the morphology, the major immunohistochemical, molecular genetic, and clinical data are included in each chapter.

This book provides clinical practitioners and the research community with detailed information on the diagnosis, prognosis, and treatment of non-Hodgkin lymphoma, taking into account the significant growth in knowledge including multiple therapeutic advances that have been achieved over the past 5-10 years. The work is subdivided into epidemiology, pathogenesis, pathology, imaging, and therapy of the non-Hodgkin lymphomas. The full range of therapeutic options are examined according to the major subtypes of non-Hodgkin lymphoma and the most up-to-date information is provided on current standard treatment options, including stem cell transplantation as well as new cutting-edge therapeutics.

A.G. STANSFELD, and J.A.M. VAN UNNIK. In joint discussions in 1974, the Club worked out a new terminology that was acceptable to all members and will hopefully be acceptable to other pathologists. Since then, it has been called the Kiel Classification. We are also pleased that the clinicians belonging to the Kiel Lymphoma Study Group-foremost A. STACHER and G. BRITTINGER have been able to present preliminary data on the clinical relevance of the new classification. Finally, our optimism was fortified by the findings of R.J. LUKES and R.D. COLLINS, which largely concur with ours in both concept and practical significance. This book is divided into six main sections. First, there is a chapter on normal cytology that supplements and, in some respects, revises the presentation given in Part A of this Handbook (1961). H.K. MULLER-HERMELINK played a major role in the writing of the first chapter. The second chapter is a brief description of the light-microscopic techniques that are used in our laboratories and have proved to be suitable for a precise diagnosis of lymph-node diseases.

This text provides a state-of-the-art overview on Non-Hodgkin's lymphoma (NHL) in children and adolescents. The volume is divided into seven sections, each of which focuses on a critical component of pediatric NHL, including history and epidemiology, pathology and molecular biology, disease evaluation and response, common and rare sub-types of NHL, and current and novel treatment strategies. The text also comprehensively reviews the late effects of treatment, quality of patient life, and NHL treatment in countries with limited resources. Written by experts in the field, Non-Hodgkin's Lymphoma in Childhood and Adolescence is a valuable resource for clinicians and practitioners who treat children and adolescents with NHL.

This is a comprehensive textbook of Hodgkin's and non-Hodgkin's lymphomas written by leaders in the field of childhood lymphomas. It includes clinical, pathologic and molecular biology of each subtype of lymphoma. The pathology chapters are comprehensive and include excellent photographs. The book is at the level of subspecialists in pediatric hematology and oncology, radiation oncology, pediatric surgery and hematopathology.

In recent years a dramatic increase in knowledge of the biology of the lymphomas has been accompanied by the emergence of new treatments offering improvements in efficacy and reduction in toxicity. In this volume an internationally recognized group of experts review relevant aspects of the biology, diagnosis and management, with particular emphasis on the emerging data available for this disease.

Thoroughly updated for its Second Edition, Non-Hodgkin Lymphomas is the definitive textbook on the biology, diagnosis, staging, and treatment of all forms of non-Hodgkin lymphomas. With backgrounds in medical and radiation oncology, molecular biology, and pathology, the editors and contributors provide an international, multidisciplinary approach to the topic. This edition is the first text using the new World Health Organization classification of non-Hodgkin lymphomas. The book offers complete coverage of the most current techniques for diagnosis, staging, and treatment, the approach to specific types of lymphoma, and special problems common to the management of patients with these disorders.

This is the third volume in the new World Health Organization series on histological and genetic typing of tumours. Tumours of the haematopoietic and lymphoid tissues are covered. This was a collaborative project of the European Association for Haematolpathology and the Society for Haematopathology and others. The WHO classification is based on the principles defined in the Revised European-American Classification of Lymphoid Neoplasms (REAL) classification. Over 50 pathologists from around the world were involved in the project and proponents of all major lymphoma and leukaemia classifications have agreed to accept the WHO as the standard classification of haematological malignancies. So this classification represents the first true world wide concensus of haematologic malignancies. Colour photographs, magnetic resonance and ultrasound images and CT scans are included.

Genetic alterations in cancer, in addition to being the fundamental drivers of tumorigenesis, can give rise to a variety of metabolic adaptations that allow cancer cells to survive and proliferate in diverse tumor microenvironments. This metabolic flexibility is different from normal cellular metabolic processes and leads to heterogeneity in cancer metabolism within the same cancer type or even within the same tumor. In this book, we delve into the complexity and diversity of cancer metabolism, and highlight how understanding the heterogeneity of cancer metabolism is fundamental to the development of effective metabolism-based therapeutic strategies. Deciphering how cancer cells utilize various nutrient resources will enable clinicians and researchers to pair specific chemotherapeutic agents with patients who are most likely to respond with positive outcomes, allowing for more cost-effective and personalized cancer therapeutic strategies.